RPAM
UTHR icon

Rhenman & Partners Asset Management’s United Therapeutics UTHR Stock Holding History

Rhenman & Partners Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,000
Closed -$3.35M – 105
2025
Q3 		$3.35M Buy
+8,000
New +$2.69M 0.37% 71

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Rhenman & Partners Asset Management's UTHR Position: Q4 2025 in Review

Rhenman & Partners Asset Management sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 8,000 shares — an estimated $3.35M sold.

Rhenman & Partners Asset Management first reported a position in UTHR in Q3 2025 and held it in 1 quarter. The position peaked at $3.35M in Q3 2025. 837 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Rhenman & Partners Asset Management reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 8,000 United Therapeutics shares in Q4 2025, an estimated $3.35M.
  • Rhenman & Partners Asset Management first reported a position in United Therapeutics in Q3 2025 and held it in 1 quarter.
  • Rhenman & Partners Asset Management's United Therapeutics position peaked at $3.35M in Q3 2025.
  • 837 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.